BioAge Labs (BIOA) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BIOA BioAge Labs

Watchlist

4.790
+0.270+5.97%

Close Feb 14 16:00 ET

4.820
+0.030+0.63%

Post 20:01 ET

171.72MMarket Cap-2.31P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch
Analysts NotebookFeb 13 06:50 ET
Citi Downgrades BioAge Labs(BIOA.US) to Hold Rating, Cuts Target Price to $7
Moomoo NewsJan 29 07:31 ET · Ratings
Morgan Stanley Downgrades BioAge Labs(BIOA.US) to Sell Rating, Cuts Target Price to $5
Moomoo NewsJan 29 07:31 ET · Ratings
BioAge Labs Faces Sell Rating Amid Safety Concerns and Uncertain Prospects
TipRanksJan 29 07:16 ET · Ratings
BioAge Labs: Strategic Shifts and Developmental Progress Support Hold Rating Amidst Inherent Risks
TipRanksJan 29 06:46 ET · Ratings
BioAge Labs Terminates Azelapra Development
MT NewswiresJan 28 10:35 ET

Comments

Analysts Notebook

Feb 13 05:50

Columns Interest in AI-Powered MedTech is on the Rise: Key Stocks to Watch

The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...

104

248

103753999

Feb 5 09:43

$BioAge Labs (BIOA.US)$ no volume

103753999

Feb 4 09:20

$BioAge Labs (BIOA.US)$ this one dead

103753999

Jan 30 07:51

$BioAge Labs (BIOA.US)$ Dead. No more hope

Jaguar8

Jan 28 08:01

NEWS

$BioAge Labs (BIOA.US)$
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
Tuesday, 28th January at 9:00 am
Advancement of next-generation APJ agonists with discontinuation of azelaprag
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibo...

BIOA BioAge Labs

Trade Overview

Capital Trend

News

Comments

Trending Stocks